NEW ANTIPLATELET DRUGS. PART 2
| Autor: | Array B. Sumarokov |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Prasugrel Antiplatelet drug medicine.medical_treatment RM1-950 ticagrelor law.invention law Diseases of the circulatory (Cardiovascular) system Medicine Pharmacology (medical) cardiovascular diseases Intensive care medicine thromboxane receptor inhibitors Clinical pharmacology business.industry Therapeutic effect elinogrel inhibitors prasugrel disaggregants thrombin receptor inhibitors RC666-701 Pharmacodynamics Therapeutics. Pharmacology Cardiology and Cardiovascular Medicine business Elinogrel Ticagrelor circulatory and respiratory physiology medicine.drug |
| Zdroj: | Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 7, Iss 5, Pp 637-643 (2016) |
| ISSN: | 2225-3653 1819-6446 |
| DOI: | 10.20996/1819-6446-2011-7-5-637-643 |
| Popis: | Antiplatelet agents are a necessary component of modern therapy of atherosclerosis. The difficulties of the antiplatelet treatment lie in balance between the necessary therapeutic effect and the risk of excessive action, leads to the bleeding. The ability to monitor antiplatelet pharmacodynamics is still very limited. Pharmacology of antiplatelet drug has been developing rapidly. New antiplatelet drugs are on their way to clinical application — prasugrel, ticagrelor , elinogrel, thromboxane receptor inhibitors, thrombin receptors inhibitors. Clinical pharmacology of these drugs is different. Practitioner should know their specifics to avoid the development of iatrogenic complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|